Morning Read: Affymetrix mulls new bid, SCOTUS hears ACA contraception case
Plus, Paul Allen puts $100 million into high-risk biotech research, more California hospitals hit by ransomware and Roger Daltrey pushes 21st Century Cures legislation.
Morning Read: Affymetrix rejects the latest takeover bid meant to derail Thermo Fisher’s offer
Also, the latest hospital cyber attack (a ransomware attack), Zika gets political, a poll on the best kind of HIMSS keynotes, and the Valeant obituaries are rolling in.
The Power of One: Redefining Healthcare with an AI-Driven Unified Platform
In a landscape where complexity has long been the norm, the power of one lies not just in unification, but in intelligence and automation.
Former Affymetrix execs make offer for company that competes with Thermo Fisher’s
The new company, called Origin Technologies, are making this play about a week before Affymetrix shareholders plan to vote on the Thermo Fisher deal. The new bid will offer shareholders $16.10 per share in cash, up from Thermo Fisher's offer of $14 per share, as the New York Times points out.